AI CuratorAI-generated
Research summary · AI summary · not yet reviewedSubjects not reportedSystematic reviewPeer review unconfirmed
Purinergic Signaling in Neurodegenerative Diseases
A systematic review examined the role of purinergic signaling in multiple sclerosis (MS) and other neurodegenerative diseases. It highlighted potential therapeutic strategies targeting purinergic receptors like A2AR and P2X7 for immunomodulation and neuroprotection.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Understanding purinergic signaling could inform future treatments for MS, providing insights into brain immunity and disease mechanisms.
What this does not prove
This review does not include original research or clinical trial data, as it compiles existing knowledge rather than presenting new findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-05
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceFrom danger to resolution: targeting purinergic signaling in CNS diseases. ↗DOI: 10.1007/s00044-026-03583-w
Supporting passages (4)
study designThis review synthesizes current understanding of purinergic signaling in CNS immunity, explores its role in disease pathogenesis, and discusses innovative therapeutic approaches.
publication date2026-10-05
findingsThis review synthesizes current understanding of purinergic signaling in CNS immunity, explores its role in disease pathogenesis, and discusses innovative therapeutic approaches.
limitationsTitle: From danger to resolution: targeting purinergic signaling in CNS diseases.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.